Human medicines European public assessment report (EPAR): Seladelpar Gilead, Seladelpar lysine dihydrate, Status: ...
On 12 December 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Seladelpar Gilead1, intended for the treatment of Primary Biliary …